Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/ KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer

被引：0

作者：

Randall, Leslie ^{[1
]}

Sukhin, Vladyslav ^{[2
]}

Colombo, Nicoletta ^{[3
,4
]}

Korach, Jacob ^{[5
]}

Matsumoto, Takashi ^{[6
]}

Lalondrelle, Susan ^{[7
]}

Vizkeleti, Julia ^{[8
]}

Samouelian, Vanessa ^{[9
]}

Salani, Ritu ^{[10
]}

Salman, Pamela ^{[11
]}

Nogueira-Rodrigues, Angelica ^{[12
]}

Ayhan, Ali ^{[13
]}

Frentzas, Sophia ^{[14
,15
]}

Cueva, Juan ^{[16
]}

Kim, Yong-Man ^{[17
]}

Petru, Edgar ^{[18
]}

Milla, Dency Pilar ^{[19
]}

Sehouli, Jalid ^{[20
]}

Saevets, Valeriya ^{[21
]}

Yamada, Karin ^{[22
]}

Li, Kan ^{[23
]}

Szamreta, Elizabeth ^{[22
]}

Nguyen, Allison Martin ^{[22
]}

Pignata, Sandro ^{[24
]}

Lorusso, Domenica ^{[25
]}

机构：

[1] Virginia Commonwealth Univ, Richmond, VA USA

[2] Grigoriev Inst Med Radiol & Oncol, Kharkiv, Ukraine

[3] Univ Milano Bicocca, Milan, Italy

[4] European Inst Oncol IRCCS, Milan, Italy

[5] Sheba Med Ctr, Tel Aviv, Israel

[6] Ehime Univ, Matsuyama, Ehime, Japan

[7] Royal Marsden, London, England

[8] Natl Inst Oncol, Ctr Radiotherapy, Budapest, Hungary

[9] Univ Montreal, Montreal, PQ, Canada

[10] Univ Calif Los Angeles, Los Angeles, CA USA

[11] Oncovida Canc Ctr, Santiago, Chile

[12] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil

[13] Baskent Univ, Turkish Soc Gynecol Oncol TRSGO, Ankara, Turkiye

[14] Monash Hlth, Melbourne, Vic, Australia

[15] Monash Univ, Melbourne, Vic, Australia

[16] Hosp Clin Univ Santiago Compostela, Dept Med Oncol, Santiago De Compostela, Spain

[17] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[18] Med Univ Graz, Graz, Austria

[19] Hosp Nacl Guillermo Almenara Irigoyen, Lima, Peru

[20] Charite Univ Med Berlin, Berlin, Germany

[21] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Chelyabinsk, Russia

[22] Merck & Co Inc, Rahway, NJ 07065 USA

[23] Merck & Co Inc, N Wales, PA USA

[24] Inst Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[25] Univ Cattolica Sacro Cuore, Rome, Italy

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S9 / S9

页数：1

共 50 条

[41] Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Oliveira, Mafalda
Rugo, Hope S.
Howell, Sacha J.
Dalenc, Florence
Cortes, Javier
Gomez, Henry L.
Hu, Xichun
Toi, Masakazu
Jhaveri, Komal
Krivorotko, Petr
Loibl, Sibylle
Murillo, Serafin Morales
Okera, Meena
Nowecki, Zbigniew
Park, Yeon Hee
Sohn, Joo Hyuk
Tokunaga, Eriko
Yousef, Samih
Zhukova, Lyudmila
Fulford, Marta
Andrews, Haylee
Wadsworth, Ian
D'Cruz, Celina
Turner, Nicholas C.
LANCET ONCOLOGY, 2024, 25 (09): : 1231 - 1244
[42] Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies
Weiss, Jared
Goldschmidt, Jerome
Andric, Zoran
Dragnev, Konstantin H.
Gwaltney, Chad
Skaltsa, Konstantina
Pritchett, Yili
Antal, Joyce M.
Morris, Shannon R.
Daniel, Davey
CLINICAL LUNG CANCER, 2021, 22 (05) : 449 - 460
[43] Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Scagliotti, Giorgio
von Pawel, Joachim
Novello, Silvia
Ramlau, Rodryg
Favaretto, Adolfo
Barlesi, Fabrice
Akerley, Wallace
Orlov, Sergey
Santoro, Armando
Spigel, David
Hirsh, Vera
Shepherd, Frances A.
Sequist, Lecia V.
Sandler, Alan
Ross, Jeffrey S.
Wang, Qiang
von Roemeling, Reinhard
Shuster, Dale
Schwartz, Brian
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) : 2667 - +
[44] Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)
Fang, J.
Zhao, Y.
Han, B.
Chen, G.
Yang, Z.
Bi, M.
Zhang, L.
Molife, C.
Zhao, Y.
Zhang, L.
ANNALS OF ONCOLOGY, 2021, 32 : S1415 - S1415
[45] IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab plus nab-paclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer
Emens, L. A.
Loi, S.
Rugo, H. S.
Schneeweiss, A.
Dieras, V.
Iwata, H.
Barrios, C. H.
Nechaeva, M.
Molinero, L.
Duc, A. Nguyen
Funke, R.
Chui, S. Y.
Husain, A.
Winer, E. P.
Adams, S.
Schmid, P.
CANCER RESEARCH, 2019, 79 (04)
[46] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
Taplin, Mary-Ellen
Gleave, Martin
Evans, Christopher P.
Efstathiou, Eleni
Kantoff, Philip W.
Ross, Ashley
Shore, Neal D.
Briganti, Alberto
Hadaschik, Boris A.
Heidenreich, Axel
Rooney, Oliver Brendan
Tian, Shaozhou Ken
Wetherhold, Lisa
Xu, Weichun
Cheng, Shinta
Kibel, Adam S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[47] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).
Kibel, Adam S.
Gleave, Martin
Brookman-May, Sabine D.
Kim, Won
Evans, Christopher P.
Efstathiou, Eleni
Kantoff, Philip W.
Ross, Ashley
Shore, Neal D.
Briganti, Alberto
Hadaschik, Boris A.
Heidenreich, Axel
Rooney, Oliver Brendan
Tian, Shaozhou Ken
Wetherhold, Lisa
Xu, Weichun
Parsons, J. Kellogg
Yeruva, Kesav
Taplin, Mary-Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[48] Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)
Agarwal, N.
McQuarrie, K.
Bjartell, A.
Chowdhury, S.
Gomes, A. J. P. D. S.
Chung, B. H.
Ozguroglu, M.
Juarez Soto, A.
Merseburger, A.
Uemura, H.
Ye, D.
Given, R.
Miladinovic, B.
Dearden, L.
Deprince, K.
Naini, V.
Lopez-Gitlitz, A.
Chi, K. N.
ANNALS OF ONCOLOGY, 2019, 30
[49] TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial
Dong, Baiqiang
Chen, Long
Pang, Qingsong
Jiang, Ou
Ge, Hong
Cheng, Yufeng
Zhou, Rongrong
Meng, Xiangjiao
Li, Jie
Zhu, Xuan
Wang, Xunqiang
Cao, Qiuyue
Ji, Yongling
Chen, Ming
TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (10)
[50] IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) plus nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
Schmid, Peter
Adams, Sylvia
Rugo, Hope S.
Schneeweiss, Andreas
Barrios, Carlos H.
Iwata, Hiroji
Dieras, Veronique
Henschel, Volkmar
Molinero, Luciana
Chui, Stephen Y.
Husain, Amreen
Winer, Eric P.
Loi, Sherene
Emens, Leisha A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →